NasdaqGS - Nasdaq Real Time Price • USD
Madrigal Pharmaceuticals, Inc. (MDGL)
As of 12:39 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 15 | 15 |
| Avg. Estimate | -6.28 | -6.61 | -23.57 | -14.69 |
| Low Estimate | -7.34 | -8.33 | -32.21 | -27.28 |
| High Estimate | -4.86 | -5.45 | -13.67 | -3.06 |
| Year Ago EPS | -4.23 | -4.69 | -19.99 | -23.57 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 12 | 12 | 12 |
| Avg. Estimate | -- | 4.3M | 89.05M | 368.05M |
| Low Estimate | -- | -- | 61.11M | 201.78M |
| High Estimate | -- | 15M | 112.4M | 509.22M |
| Year Ago Sales | -- | -- | -- | 89.05M |
| Sales Growth (year/est) | -- | -- | -- | 313.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -4.94 | -4.58 | -4.92 | -5.28 |
| EPS Actual | -4.23 | -4.69 | -5.34 | -5.68 |
| Difference | 0.71 | -0.11 | -0.42 | -0.4 |
| Surprise % | 14.40% | -2.40% | -8.50% | -7.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -6.28 | -6.61 | -23.57 | -14.69 |
| 7 Days Ago | -6.3 | -6.62 | -23.48 | -14.46 |
| 30 Days Ago | -6.3 | -6.62 | -23.48 | -14.46 |
| 60 Days Ago | -5.05 | -5.36 | -16.77 | -3.79 |
| 90 Days Ago | -5.02 | -5.29 | -16.4 | -3.18 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MDGL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -48.50% | -- | -- | 1.50% |
| Next Qtr. | -40.90% | -- | -- | 11.40% |
| Current Year | -17.90% | -- | -- | 5.20% |
| Next Year | 37.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 0.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | B of A Securities: Underperform | 4/22/2024 |
| Maintains | Evercore ISI Group: Outperform to Outperform | 3/20/2024 |
| Maintains | UBS: Buy to Buy | 3/15/2024 |
| Maintains | TD Cowen: Outperform to Outperform | 3/15/2024 |
| Maintains | Citigroup: Buy to Buy | 3/15/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/15/2024 |
Related Tickers
VKTX Viking Therapeutics, Inc.
66.81
+2.67%
DAWN Day One Biopharmaceuticals, Inc.
13.27
-12.67%
AXSM Axsome Therapeutics, Inc.
71.29
+0.17%
CYTK Cytokinetics, Incorporated
65.00
-2.72%
ALT Altimmune, Inc.
7.00
-1.13%
IOVA Iovance Biotherapeutics, Inc.
11.39
-2.78%
AKRO Akero Therapeutics, Inc.
19.00
-6.24%
TGTX TG Therapeutics, Inc.
13.62
-2.58%
BHVN Biohaven Ltd.
38.51
-0.54%
JANX Janux Therapeutics, Inc.
47.25
-1.99%